Clinical Trial Update: Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis [Phase 2]

View source ↗

Summary

Phase 2 open-label study evaluating the safety of levocetirizine in children aged 2-6 with allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• XYZAL (LEVOCETIRIZINE DIHYDROCHLORIDE)

Snippet

Sponsor: UCB Pharma | Conditions: Allergic Rhinitis | Phase 2 | Status: COMPLETED